We have used different colon cancer samples and cell lines (SW480, SW620, SW48, KM12C and KM12SM) [29], [30], [31] to investigate the presence of SNPs or activating mutations in FGFR4 and to characterize its biological relevance as oncogene and therapeutic target in colorectal cancer. The gene discussed is FGFR4; the disease is malignant colon neoplasm.